Learn more about whether Moderna, Inc. or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Moderna, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...

GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax ... That rise came despite the approval of Merck & Co's 15-valent Vaxneuvance in July 2021, which has ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Concluding 18 months of drafting, the City of Cambridge announced the final design of the Mass. Ave Planning Study at a ...

The Symposium will feature scientific leaders who are creating cutting edge technologies and approaches for building the ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE: MRK) stands against other stocks that Jim Cramer discussed recently. On Wednesday, Jim Cramer, the host of Mad Money ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...